2024
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Medjimorec M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nature Communications 2024, 15: 2839. PMID: 38565563, PMCID: PMC10987549, DOI: 10.1038/s41467-024-46540-0.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatitis, AtopicHumansInterleukin-13Severity of Illness IndexT-LymphocytesTreatment OutcomeConceptsHead and neck dermatitisAtopic dermatitisNeck dermatitisT cellsHealthy control skinType 2 inflammationDupilumab treatmentImmune signaturesReceptor upregulationActivation markersClinical efficacyPunch biopsyHistopathological featuresDe novo appearanceIL-22Single-cell RNA sequencingDrug effectsDupilumabSide effectsControl skinDermatitisKeratinocyte activationUntreated ADTreatmentRNA sequencing
2023
Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBiopsyEczemaHumansMachine LearningSkinTreatment OutcomeImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsInterleukin-13Pemphigoid, BullousConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2022
Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression
Ahmad M, Murphy M, Damsky W, Leventhal J. Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. International Journal Of Dermatology 2022, 62: e424-e426. PMID: 36468831, DOI: 10.1111/ijd.16538.Peer-Reviewed Original Research
2021
Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report
Mirza F, Wang A, Ramachandran S, Damsky W, Cohen J. Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report. British Journal Of Dermatology 2021, 185: 432-434. PMID: 33730377, DOI: 10.1111/bjd.20064.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedDermatitis, AtopicHumansInterleukin-17PhenotypePsoriasisConceptsInterleukin-17A expression